SCHEMBL5134950

SCHEMBL5134950

CCCCN(Cc1ccc(Cl)cc1)Cc1c(-c2ccc(Cl)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
TSHR P16473 1/20 0.41
CRHR1 P34998 4/20 0.41
MAPT P10636 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
SLC2A1 P11166 1/20 0.39
BCHE P06276 3/20 0.39
ATP4A P20648 1/20 0.39
ATP4B P51164 1/20 0.39
HSD11B1 P28845 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135824 0.99 C5AR1 (0.44) C5AR1TSHRCRHR1MAPTKDM4E
SCHEMBL5136524 0.99 C5AR1 (0.46) C5AR1TSHRCRHR1MAPTKDM4E
SCHEMBL5134667 0.97 C5AR1 (0.43) C5AR1TSHRCRHR1MAPTKDM4E
SCHEMBL5136847 0.97 MAPT (0.44) C5AR1TSHRCRHR1MAPTKDM4E
SCHEMBL5136887 0.96 C5AR1 (0.43) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5136560 0.95 C5AR1 (0.46) C5AR1TSHRCRHR1MAPTKDM4E
SCHEMBL5136269 0.95 CRHR1 (0.42) C5AR1TSHRCRHR1ALDH1A1SLC2A1
SCHEMBL5134621 0.94 CASR (0.43) C5AR1TSHRCRHR1MAPTKDM4E
SCHEMBL5137489 0.94 C5AR1 (0.48) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5137477 0.94 CRHR1 (0.43) C5AR1TSHRCRHR1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed